Feasibility study for a microchip-based approach for noninvasive prenatal diagnosis of genetic diseases

L. Cremonesi, S. Galbiati, B. Foglieni, M. Smid, D. Gambini, A. Ferrari, E. Viora, M. Campogrande, M. Pagliano, M. Travi, A. Piga, G. Restagno, M. Ferrari

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Fetal DNA in maternal plasma may represent a source of genetic material for prenatal noninvasive diagnosis of genetic diseases. We evaluated a cohort of physiological pregnancies to determine if fetal DNA can be retrieved at any gestational week in sufficient quantity to be analyzed with advanced mutation detection technologies. We performed fetal DNA quantification by real-time polymerase chain reaction (PCR) on the SRY gene in 356 women sampled from 6 to 40 gestational weeks. Fetal DNA was retrieved at any week. All female fetuses were correctly identified. In 5 of 188 (2.6%) male-bearing pregnancies, no amplification was obtained. For noninvasive testing, complete clearance of fetal DNA after delivery is mandatory. Long-term persistence was not detected in women with previous sons or abortions. These findings confirm that maternal plasma may represent the optimal source of fetal genetic material. For noninvasive diagnosis of genetic diseases, we evaluated microchip technology. The detection limit for a minority allele determined by diluting a mutated DNA into a wild-type plasma sample was 5 genome equivalents, indicating that the test might be applied to the identification of paternally inherited fetal alleles in maternal plasma. The addition of peptide nucleic acids (PNAs) to either the PCR reaction or the chip hybridization mixture allowed approximately 50% inhibition of wild-type allele signals.

Original languageEnglish
Pages (from-to)105-112
Number of pages8
JournalAnnals of the New York Academy of Sciences
Volume1022
DOIs
Publication statusPublished - 2004

Fingerprint

Inborn Genetic Diseases
Feasibility Studies
Prenatal Diagnosis
DNA
Plasmas
Polymerase chain reaction
Alleles
Mothers
Bearings (structural)
Genes
Peptide Nucleic Acids
Technology
Pregnancy
Nuclear Family
Amplification
Limit of Detection
Genetic Disease
Real-Time Polymerase Chain Reaction
Fetus
Genome

Keywords

  • Circulating DNA
  • Fetal DNA
  • Maternal plasma
  • Noninvasive prenatal diagnosis

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Feasibility study for a microchip-based approach for noninvasive prenatal diagnosis of genetic diseases. / Cremonesi, L.; Galbiati, S.; Foglieni, B.; Smid, M.; Gambini, D.; Ferrari, A.; Viora, E.; Campogrande, M.; Pagliano, M.; Travi, M.; Piga, A.; Restagno, G.; Ferrari, M.

In: Annals of the New York Academy of Sciences, Vol. 1022, 2004, p. 105-112.

Research output: Contribution to journalArticle

Cremonesi, L, Galbiati, S, Foglieni, B, Smid, M, Gambini, D, Ferrari, A, Viora, E, Campogrande, M, Pagliano, M, Travi, M, Piga, A, Restagno, G & Ferrari, M 2004, 'Feasibility study for a microchip-based approach for noninvasive prenatal diagnosis of genetic diseases', Annals of the New York Academy of Sciences, vol. 1022, pp. 105-112. https://doi.org/10.1196/annals.1318.017
Cremonesi, L. ; Galbiati, S. ; Foglieni, B. ; Smid, M. ; Gambini, D. ; Ferrari, A. ; Viora, E. ; Campogrande, M. ; Pagliano, M. ; Travi, M. ; Piga, A. ; Restagno, G. ; Ferrari, M. / Feasibility study for a microchip-based approach for noninvasive prenatal diagnosis of genetic diseases. In: Annals of the New York Academy of Sciences. 2004 ; Vol. 1022. pp. 105-112.
@article{5c4754a2155c4ad39567f3e41d491a99,
title = "Feasibility study for a microchip-based approach for noninvasive prenatal diagnosis of genetic diseases",
abstract = "Fetal DNA in maternal plasma may represent a source of genetic material for prenatal noninvasive diagnosis of genetic diseases. We evaluated a cohort of physiological pregnancies to determine if fetal DNA can be retrieved at any gestational week in sufficient quantity to be analyzed with advanced mutation detection technologies. We performed fetal DNA quantification by real-time polymerase chain reaction (PCR) on the SRY gene in 356 women sampled from 6 to 40 gestational weeks. Fetal DNA was retrieved at any week. All female fetuses were correctly identified. In 5 of 188 (2.6{\%}) male-bearing pregnancies, no amplification was obtained. For noninvasive testing, complete clearance of fetal DNA after delivery is mandatory. Long-term persistence was not detected in women with previous sons or abortions. These findings confirm that maternal plasma may represent the optimal source of fetal genetic material. For noninvasive diagnosis of genetic diseases, we evaluated microchip technology. The detection limit for a minority allele determined by diluting a mutated DNA into a wild-type plasma sample was 5 genome equivalents, indicating that the test might be applied to the identification of paternally inherited fetal alleles in maternal plasma. The addition of peptide nucleic acids (PNAs) to either the PCR reaction or the chip hybridization mixture allowed approximately 50{\%} inhibition of wild-type allele signals.",
keywords = "Circulating DNA, Fetal DNA, Maternal plasma, Noninvasive prenatal diagnosis",
author = "L. Cremonesi and S. Galbiati and B. Foglieni and M. Smid and D. Gambini and A. Ferrari and E. Viora and M. Campogrande and M. Pagliano and M. Travi and A. Piga and G. Restagno and M. Ferrari",
year = "2004",
doi = "10.1196/annals.1318.017",
language = "English",
volume = "1022",
pages = "105--112",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Feasibility study for a microchip-based approach for noninvasive prenatal diagnosis of genetic diseases

AU - Cremonesi, L.

AU - Galbiati, S.

AU - Foglieni, B.

AU - Smid, M.

AU - Gambini, D.

AU - Ferrari, A.

AU - Viora, E.

AU - Campogrande, M.

AU - Pagliano, M.

AU - Travi, M.

AU - Piga, A.

AU - Restagno, G.

AU - Ferrari, M.

PY - 2004

Y1 - 2004

N2 - Fetal DNA in maternal plasma may represent a source of genetic material for prenatal noninvasive diagnosis of genetic diseases. We evaluated a cohort of physiological pregnancies to determine if fetal DNA can be retrieved at any gestational week in sufficient quantity to be analyzed with advanced mutation detection technologies. We performed fetal DNA quantification by real-time polymerase chain reaction (PCR) on the SRY gene in 356 women sampled from 6 to 40 gestational weeks. Fetal DNA was retrieved at any week. All female fetuses were correctly identified. In 5 of 188 (2.6%) male-bearing pregnancies, no amplification was obtained. For noninvasive testing, complete clearance of fetal DNA after delivery is mandatory. Long-term persistence was not detected in women with previous sons or abortions. These findings confirm that maternal plasma may represent the optimal source of fetal genetic material. For noninvasive diagnosis of genetic diseases, we evaluated microchip technology. The detection limit for a minority allele determined by diluting a mutated DNA into a wild-type plasma sample was 5 genome equivalents, indicating that the test might be applied to the identification of paternally inherited fetal alleles in maternal plasma. The addition of peptide nucleic acids (PNAs) to either the PCR reaction or the chip hybridization mixture allowed approximately 50% inhibition of wild-type allele signals.

AB - Fetal DNA in maternal plasma may represent a source of genetic material for prenatal noninvasive diagnosis of genetic diseases. We evaluated a cohort of physiological pregnancies to determine if fetal DNA can be retrieved at any gestational week in sufficient quantity to be analyzed with advanced mutation detection technologies. We performed fetal DNA quantification by real-time polymerase chain reaction (PCR) on the SRY gene in 356 women sampled from 6 to 40 gestational weeks. Fetal DNA was retrieved at any week. All female fetuses were correctly identified. In 5 of 188 (2.6%) male-bearing pregnancies, no amplification was obtained. For noninvasive testing, complete clearance of fetal DNA after delivery is mandatory. Long-term persistence was not detected in women with previous sons or abortions. These findings confirm that maternal plasma may represent the optimal source of fetal genetic material. For noninvasive diagnosis of genetic diseases, we evaluated microchip technology. The detection limit for a minority allele determined by diluting a mutated DNA into a wild-type plasma sample was 5 genome equivalents, indicating that the test might be applied to the identification of paternally inherited fetal alleles in maternal plasma. The addition of peptide nucleic acids (PNAs) to either the PCR reaction or the chip hybridization mixture allowed approximately 50% inhibition of wild-type allele signals.

KW - Circulating DNA

KW - Fetal DNA

KW - Maternal plasma

KW - Noninvasive prenatal diagnosis

UR - http://www.scopus.com/inward/record.url?scp=3242670445&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3242670445&partnerID=8YFLogxK

U2 - 10.1196/annals.1318.017

DO - 10.1196/annals.1318.017

M3 - Article

VL - 1022

SP - 105

EP - 112

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

ER -